Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (711)	4/17/2007 12:51:33 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

The stock is still trading above $5 after announcing yesterday its updated ADVEXIN biomarker data at the AACR meeting. INGN has amended its PIII plan and INDA with the FDA to incorporate the use of the p53 biomarker, trying to support the licensure of ADVEXIN. It also presented at the AACR data on its INGN 241, which is also on a PIII, indicating that inhibitors of heat shock proteins enhances INGN 241-mediated apoptosis. These data provide insight into its mechanisms of action and possible future strategies. biz.yahoo.com INGN also said yesterday that regulators in Europe certified its production facilities for Advexin. As previously mentioned,it seems that Cramer,Feurstein, et al may have to come out again to try to save the shorts.<g> Bernard